Iopidine

Apraclonidine, the active ingredient in Iopidine, is a alpha-2 adrenergic agonist presented as eye drops for ocular use. It is employed to lower intra‑ocular pressure in glaucoma and post‑operative ocular hypertension. GNH USA supplies Iopidine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iopidine (apraclonidine) is used in ocular conditions that involve elevated intra‑ocular pressure.

Glaucoma: provides adjunctive pressure reduction when other agents are insufficient. Post‑operative ocular hypertension: helps control pressure spikes after eye surgery. Elevated intra‑ocular pressure: lowers pressure to prevent optic nerve damage.

Common Side Effects: - Ocular burning or stinging sensation. - Transient eye redness or hyperemia. - Itching or mild irritation of the conjunctiva. - Blurred vision shortly after instillation.

Serious or Rare Side Effects: - Severe allergic reaction with eyelid edema or systemic rash. - Stevens‑Johnson syndrome or severe ocular inflammation. - Marked systemic hypotension when used with other alpha‑2 agonists. - Cardiac arrhythmias in susceptible patients.

Before using Iopidine, consider the following precautions: - Monitor intra‑ocular pressure regularly to assess therapeutic response. - Use with caution in patients with cardiovascular disease or uncontrolled hypertension. - Avoid in individuals with known hypersensitivity to apraclonidine or formulation excipients. - Caution when combined with other ocular hypotensive agents to prevent excessive pressure lowering. - Do not wear contact lenses during treatment unless advised by an eye care professional. - Store at room temperature: keep in the original container, protect from light and moisture.

Iopidine may interact with other medications as follows:

Major Interactions (Avoid): - Systemic alpha‑2 agonists (e.g., clonidine): additive hypotensive effect. - Non‑selective beta‑blockers: may diminish Iopidine's pressure‑lowering efficacy. - Other ocular hypotensive agents: risk of excessive intra‑ocular pressure reduction.

Moderate Interactions (Monitor Closely):\n- Topical anesthetics: may increase ocular irritation. - Antihistamine eye drops: potential for reduced therapeutic effect. - Systemic antihypertensives: monitor blood pressure for additive lowering. - MAO inhibitors: observe for possible systemic cardiovascular effects.